Publications

Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer

Viral Kinetics During 14-day Treatment with Debio-025 Demonstrate Efficient Blocking of Viral Replication in Different HCV Genotypes without Signs of…

The Reduction of both Cyclophilin B and HCV-RNA by the Cyclophilin Inhibitor Debio-025 Confirms the Importance of Cyclophilin B for…

Low Risk of Drug Interaction between the Cyclophilin Inhibitor Debio-025 and (Peg) IFNa/ribavirin in HCV

Review of Current and Investigational Pharmacologic Agents for Acute Heart Failure Syndromes

Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins

The cyclophilin inhibitor DEBIO-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naïve HIV/HCV co-infected subjects

Non-immunosuppressive Cyclosporin Debio-025 with Interferon shows synergistic Anti-HCV Effect in Chimeric Mouse

Multiple-target chemotherapy (LV-modulated 5-FU bolus and continuous infusion, oxaliplatin, CPT- 11) in advanced 5-FU-refractory colorectal cancer: MTD definition and efficacy…